Biogen ramps up its SMA rivalry with Novartis with new Spinraza trial

18th September 2019 Uncategorised 0

In its latest gambit to preserve market share in spinal muscular atrophy, Biogen’s launching a new Spinraza trial designed to determine whether a higher dose might be more effective than the one already FDA-approved.

More: Biogen ramps up its SMA rivalry with Novartis with new Spinraza trial
Source: fierce